Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleResearch

Development of Matrix-Type Transdermal Delivery of Lornoxicam: In Vitro Evaluation and Pharmacodynamic and Pharmacokinetic Studies in Albino Rats

Dheeraj T. Baviskar, Venkatesh B. Parik and Dinesh J. Jain
PDA Journal of Pharmaceutical Science and Technology January 2013, 67 (1) 9-22; DOI: https://doi.org/10.5731/pdajpst.2013.00898
Dheeraj T. Baviskar
1Institute of Pharmaceutical Education, Boradi, Shirpur, Dhule 425428 (M.H.) India and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: baviskar@sancharnet.in
Venkatesh B. Parik
1Institute of Pharmaceutical Education, Boradi, Shirpur, Dhule 425428 (M.H.) India and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinesh J. Jain
2College of Pharmacy, I.P.S. Academy, Rajendra Nagar, Indore 452012 (M.P.) India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

A matrix-type transdermal drug delivery system of lornoxicam was prepared with the addition of combination of hydrophilic and hydrophobic polymers in different ratios. Transdermal patches of lornoxicam were designed with ethyl cellulose:polyvinylpyrrolidone and Eudragit RL 100:Eudragit RS 100 in different ratios with propylene glycol as plasticizer (5%) and tween 80 as permeation enhancer using the solvent evaporation technique. Evaluation of these formulations was performed through mechanical characterization and in vitro permeation studies. From the physicochemical and in vitro permeation data, the two formulations showing the best result (A3 and B3) were selected for further in vivo studies. The anti-inflammatory and analgesic effects of the patches were studied using the carrageenan paw edema model and hot plate test, respectively. The pharmacokinetic parameters were studied and recorded on animals. Formulations A3 and B3 exhibited greatest (311.04 μg and 306.32 μg, respectively) cumulative amount of drug release. The Higuchi model seemed to be the most appropriate model describing release kinetics from all patches (r2 = 0.9847–0.9971). It was observed that both the patches significantly controlled inflammation and showed analgesic effect from the first hour (P < 0.05). Formulations A3 and B3 were found to enhance the bioavailability of lornoxicam by 3.1 and 2.7 times, respectively, with reference to the oral dosage form. Hence, lornoxicam can be formulated into transdermal patches to sustain its release characteristics and to avoid the disadvantages of oral routes. Formulations A3 and B3 were found to be the best choice to manufacture a lornoxicam transdermal drug delivery system.

LAY ABSTRACT: The objective of the present work was to develop a matrix-type transdermal drug delivery system of lornoxicam with the addition of ethyl cellulose:polyvinylpyrrolidone and Eudragit RL 100:Eudragit RS 100 in different ratios with propylene glycol as plasticizer (5%) and tween 80 as permeation enhancer using the solvent evaporation technique. Lornoxicam is a non-steroidal anti-inflammatory drug that is used for the treatment of pain, inflammation, and arthritis. The prepared patches were evaluated for mechanical characterization and in vitro permeation studies. The formulations showing best results (A3 and B3) were selected further for in vivo and pharmacokinetic studies on animals. From the results, it was found that formulations A3 and B3 exhibited greatest cumulative amount of drug release, controlled inflammation, and showed analgesic effect from the first hour. Hence, lornoxicam can be formulated into transdermal patches, and formulations A3 and B3 were found to be the best choice to manufacture a lornoxicam transdermal drug delivery system.

  • Transdermal
  • Lornoxicam
  • In vitro permeation
  • Anti-inflammatory
  • Analgesic
  • Pharmacokinetic
  • Eudragit
  • © PDA, Inc. 2013
View Full Text

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to pda.org users

The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

Full issue PDFs are for PDA members only. You can join PDA at www.pda.org. 

PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 67 (1)
PDA Journal of Pharmaceutical Science and Technology
Vol. 67, Issue 1
January/February 2013
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of Matrix-Type Transdermal Delivery of Lornoxicam: In Vitro Evaluation and Pharmacodynamic and Pharmacokinetic Studies in Albino Rats
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of Matrix-Type Transdermal Delivery of Lornoxicam: In Vitro Evaluation and Pharmacodynamic and Pharmacokinetic Studies in Albino Rats
Dheeraj T. Baviskar, Venkatesh B. Parik, Dinesh J. Jain
PDA Journal of Pharmaceutical Science and Technology Jan 2013, 67 (1) 9-22; DOI: 10.5731/pdajpst.2013.00898

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of Matrix-Type Transdermal Delivery of Lornoxicam: In Vitro Evaluation and Pharmacodynamic and Pharmacokinetic Studies in Albino Rats
Dheeraj T. Baviskar, Venkatesh B. Parik, Dinesh J. Jain
PDA Journal of Pharmaceutical Science and Technology Jan 2013, 67 (1) 9-22; DOI: 10.5731/pdajpst.2013.00898
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • 1. Introduction
    • 2. Materials and Methods
    • 3. Results and Discussion
    • 4. Conclusions
    • Conflict of Interest Statement
    • Acknowledgements
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Holistic Approach for Filling Volume Variability Evaluation and Control with Statistical Tool
  • A Proof-of-Concept Study on a Universal Standard Kit to Evaluate the Risks of Inspectors for Their Foundational Ability of Visual Inspection of Injectable Drug Products
  • Quantitative and Qualitative Evaluation of Microorganism Profile Identified in Bioburden Analysis in a Biopharmaceutical Facility in Brazil: Criteria for Classification and Management of Results
Show more Research

Similar Articles

Keywords

  • Transdermal
  • Lornoxicam
  • In vitro permeation
  • Anti-inflammatory
  • Analgesic
  • Pharmacokinetic
  • Eudragit

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire